- Home
- ATRC vs TARS Comparison
ATRC vs TARS Comparison
Compare ATRC & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRC
- TARS
- Stock Information
- Founded
- ATRC 2000
- TARS 2016
- Country
- ATRC United States
- TARS United States
- Employees
- ATRC N/A
- TARS N/A
- Industry
- ATRC Medical/Dental Instruments
- TARS Medicinal Chemicals and Botanical Products
- Sector
- ATRC Health Care
- TARS Health Care
- Exchange
- ATRC Nasdaq
- TARS Nasdaq
- Market Cap
- ATRC 1.6B
- TARS 1.7B
- IPO Year
- ATRC 2005
- TARS 2020
- Fundamental
- Price
- ATRC $35.31
- TARS $47.85
- Analyst Decision
- ATRC Strong Buy
- TARS Strong Buy
- Analyst Count
- ATRC 10
- TARS 7
- Target Price
- ATRC $49.60
- TARS $67.14
- AVG Volume (30 Days)
- ATRC 712.5K
- TARS 642.5K
- Earning Date
- ATRC 07-29-2025
- TARS 08-06-2025
- Dividend Yield
- ATRC N/A
- TARS N/A
- EPS Growth
- ATRC N/A
- TARS N/A
- EPS
- ATRC N/A
- TARS N/A
- Revenue
- ATRC $499,946,000.00
- TARS $295,521,000.00
- Revenue This Year
- ATRC $14.63
- TARS $122.94
- Revenue Next Year
- ATRC $12.62
- TARS $44.14
- P/E Ratio
- ATRC N/A
- TARS N/A
- Revenue Growth
- ATRC 16.28
- TARS 254.45
- 52 Week Low
- ATRC $20.20
- TARS $22.58
- 52 Week High
- ATRC $43.11
- TARS $57.28
- Technical
- Relative Strength Index (RSI)
- ATRC 58.24
- TARS 68.69
- Support Level
- ATRC $33.63
- TARS $40.55
- Resistance Level
- ATRC $37.80
- TARS $42.11
- Average True Range (ATR)
- ATRC 1.64
- TARS 1.75
- MACD
- ATRC 0.48
- TARS 0.72
- Stochastic Oscillator
- ATRC 68.47
- TARS 95.60
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.